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Abstract 24 
While it is clear that high-risk human papillomaviruses (hrHPVs) can selectively infect 25 
keratinocytes and persist in the host, it still remains to be unequivocally determined whether they 26 
can escape antiviral innate immunity by interfering with pattern recognition receptor (PRR) 27 
signaling. Here, we have assessed the innate immune response in monolayer and organotypic raft 28 
cultures of NIKS cells harboring multiple copies of episomal HPV18 (named NIKSmcHPV18), 29 
which fully recapitulate the persistent state of infection. We show for the first time that 30 
NIKSmcHPV18, as well as HeLa cells (a cervical carcinoma-derived cell line harboring 31 
integrated HPV18 DNA) display marked downregulation of several PRRs as well as other PRR 32 
downstream effectors such as the adaptor protein STING and the transcription factors IRF1 and 33 
IRF7. Importantly, we provide evidence that downregulation of STING, cGAS, and RIG-I 34 
mRNA levels occurs at the transcriptional level through a novel epigenetic silencing mechanism 35 
as documented by the accumulation of repressive heterochromatin markers seen at the promoter 36 
region of these genes. Furthermore, stimulation of NIKSmcHPV18 cells with salmon sperm 37 
DNA (SS DNA) or poly(dA:dT), two potent inducers of PRR signaling, only partially restored 38 
PRR protein expression. Accordingly, the production of both IFN-β and IFN-λ1 was significantly 39 
reduced in comparison to parental NIKS cells, indicating that HPV18 exerts its 40 
immunosuppressive activity through downregulation of PRR signaling. Altogether, our findings 41 
indicate that hrHPV have evolved broad-spectrum mechanisms that allow simultaneous depletion 42 
of multiple effectors of the innate immunity network, thereby creating an unreactive cellular 43 
milieu suitable for viral persistence.  44 
 45 
 46 
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Introduction 47 
Human papillomaviruses (HPVs) comprise a large family of sexually transmitted DNA 48 
viruses, which can cause both benign and malignant lesions in humans (1-4, 49 
https://pave.niaid.nih.gov/). Although it has been known for quite some time that HPVs are able 50 
to evade the innate immune response and persist in the host, the molecular mechanisms 51 
regulating these critical events have only recently begun to emerge and still remain largely 52 
uncharacterized (5-7). Thus, gaining mechanistic insights into the immune escape by HPVs 53 
would allow us to better understand how these viruses can favor cancer progression.  54 
Among the HPV family members, high-risk HPV (hrHPV) genotypes, especially HPV16 55 
and 18, selectively infect human keratinocytes (KCs) in stratified epithelia of mucosa leading to 56 
epithelial hyperplasia, which can subsequently progress to cancer at different anatomical sites, 57 
such as the anogenital tract and oropharynx (8, 9). Since undifferentiated KCs express several 58 
pattern recognition receptors (PRRs), which are able to sense viral pathogens and promote the 59 
innate immune response (10-12), it is highly likely that hrHPVs have developed effective 60 
strategies to evade the innate immunity by inhibiting PRR downstream signaling (13-16). In 61 
support of this hypothesis, a recent report by Laura Lau and co-workers has shown that E6 and 62 
E7 deregulation in transformed KCs antagonizes the cGAS-STING pathway. In particular, E7 63 
was found to directly bind STING, thereby acting as a specific antagonist of the DNA-activated 64 
antiviral response (17). In addition, others have shown that E6 or E7 protein from hrHPV 65 
genotypes inhibits the transcriptional activity of IRF family members (18-22). However, there 66 
are several caveats affecting the interpretation and generalizability of the aforementioned 67 
findings such as the heterogeneity of the cell models employed (e.g. cells of different origin such 68 
as epithelial cells and fibroblasts, cells overexpressing only E6 and E7, cells transfected with 69 
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episomal viral genomes, or transformed cells harboring multiple copies of the integrated viral 70 
genome) and the multiplicity of stimuli used to test host innate immunity. Thus, while it is clear 71 
that hrHPVs can selectively infect basal KCs and persist in the host, it still remains to be 72 
unequivocally determined how, in HPV-infected KCs, the physical status of the virus, different 73 
cell-type specific microenvironments, or different stimuli may affect the host innate antiviral 74 
response. Furthermore, whether HPV interferes with the expression of PRRs in HPV episome-75 
containing KCs still remains an open question. Thus, there is a significant gap in our knowledge 76 
of the pathogenic mechanisms of hrHPV in human KCs. 77 
The interferon (IFN) system constitutes the first line of defense against viruses in 78 
mammals. IFNs are categorized into three groups: type I [alpha/beta IFN (IFN-a/β)], type II 79 
[gamma IFN (IFN-g)], and type III [lambda IFN (IFN-λ)]. Among them, IFN-λ is the most 80 
recently described group of small helical cytokines capable of inducing an antiviral state in 81 
responsive cells (23-26). Although type I IFNs act in most mammalian cell types, type III IFNs 82 
appear to primarily target mucosal surfaces, particularly epithelial cells of the intestine, liver, 83 
lung, and presumably skin (27-29).  84 
In this study, we have deliberately chosen as our cell model the near-diploid, 85 
spontaneously immortalized human keratinocyte cell line (NIKS), which retains a normal 86 
response to contact inhibition, supports the full productive HPV life cycle, and provides an 87 
isogenic cell background where to study virus-host interactions (30, 31). Using this cell model, 88 
which recapitulates the full viral life cycle of HPV, we show that NIKS cells harboring multiple 89 
copies of episomal HPV18 genomes fail to produce both type I and III IFNs not only under 90 
differentiating conditions, but also following exposure to either salmon sperm DNA (SS DNA) 91 
or poly(dA:dT), two potent inducers of PRR signaling (32-35). Lastly, we report the existence of 92 
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multiple evasion mechanisms relying on HPV18-mediated transcriptional inhibition of key 93 
components of the cGAS-STING and RIG-I DNA-sensing pathways.  94 
Overall, our findings provide novel insights into HPV18 immune escape mechanisms in 95 
human KCs with possible implications in cervical carcinogenesis.  96 
 97 
 98 
 99 
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Materials and Methods 116 
Cell culture, transfection, and treatments.  117 
NIKS cells (Stratatech Corporation) were cultured in the presence of J2 3T3 fibroblast 118 
feeders as previously described (36). HeLa cells were grown in DMEM (Sigma-Aldrich) 119 
supplemented with 10% FBS (Sigma-Aldrich). HPV18 minicircle genome was produced as 120 
previously described (37). Briefly, for construction of minicircle viral genomes, a BglII site was 121 
introduced into the HPV18 genome after nucleotide 7,473 and the minicircle vector 122 
pMC.BESPX was subcloned into this site. For the production of minicircles, the Escherichia coli 123 
strain ZYCY10P3S2T was transformed and grown in TB medium until an optical density at 600 124 
nm (OD600) of 4-5 was reached. An equal volume of induction mix (0.04 N NaOH and 0.02% 125 
L-arabinose in LB broth) was added to induce recombination, and the culture was incubated for 126 
an additional 5 h at 32°C. Subsequently, plasmid DNA was extracted from bacteria and gel 127 
purified to obtain only the covalently closed circular DNA (cccDNA) form of the viral genome. 128 
NIKSmcHPV18 cells were obtained by nucleofection of NIKS cells with Nucleofector II 129 
Amaxa (Biosystems) with 2 µg of HPV18 minicircles according to the manufacturer’s 130 
instructions, grown as pooled cells, and used from passages 20 to 30. Organotypic raft cultures 131 
were generated as previously described in Wilson and Laimins, 2005 (38). Briefly, organotypic 132 
cultures were grown in specialized culture chambers on a collagen base, formed by mixing 133 
normal human neonatal fibroblast with Collagen I Rat Tail (Sigma) in Ham’s F-12 medium 134 
containing 10% FBS and penicillin/streptomycin. NIKS cells were plated on the collagen base 135 
and after 15 days, raft cultures were harvested and fixed in 10% buffered formalin, embedded in 136 
paraffin, and cut into 5-μm sections for immunostaining analysis. 137 
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Poly(dA:dT) (1.25 μg/ml) and sheared salmon sperm DNA (SS DNA) (1.25 μg/ml) 138 
(InvivoGen) were transfected into the cells using Lipofectamine 3000 according to the 139 
manufacturer’s instructions (Thermo Fisher Scientific). Cells were treated with carbonyl cyanide 140 
m-chlorophenylhydrazone (CCCP; Sigma-Aldrich) at 10 μM concentration or DMSO for 30 min 141 
and then transfected for 24 h with poly(dA:dT). MG132 (Sigma-Aldrich) was used at 30 μM 142 
concentration for 8 h. 143 
 144 
Immunoblotting and native page.  145 
Whole-cell protein extracts were prepared and subjected to immunoblot analysis as 146 
previously described (39). The following antibodies were used: rabbit polyclonal antibodies anti-147 
cGAS (HPA031700; Sigma-Aldrich, diluted 1:500), RIG-I (06-1040; Merck Millipore, diluted 148 
1:10000), IFI16 (C-terminal, diluted 1:1000), IRF7 (sc-9083; Santa Cruz, diluted 1:200), IRF3 149 
(sc-9082; Santa Cruz, diluted 1:500), rabbit monoclonal antibodies anti-IRF1 (8478; Cell 150 
Signaling, diluted 1:250), pSTAT1 (9167; Cell Signaling, diluted 1:1000), or mouse monoclonal 151 
antibodies (MAb) anti-STING (MAB7169; R&D Systems, 1:1500), MAVS (sc-166583; Santa 152 
Cruz, diluted 1:200), STAT1 (610186; BD Biosciences, diluted 1:1000); MAb against α-tubulin 153 
(39527; Active Motif, diluted 1:4000) were used as a control for protein loading. 154 
Immunocomplexes were detected using sheep anti-mouse or donkey anti-rabbit immunoglobulin 155 
antibodies conjugated to horseradish peroxidase (HRP) (GE Healthcare Europe GmbH) and 156 
visualized by enhanced chemiluminescence (Super Signal West Pico; Thermo Fisher Scientific). 157 
Native polyacrylamide gel electrophoresis (PAGE) was performed using ReadyGels (7.5%; Bio-158 
Rad) as described previously (40). In brief, the gel was pre-run with 25 mM Tris base and 192 159 
mM glycine, pH 8.4, with 1% deoxycholate (DOC) in the cathode chamber for 30 min at 40 mA. 160 
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Samples in native sample buffer (20 μg protein, 62.5 mM Tris-HCl [pH 6.8], 10% glycerol, and 161 
1% DOC) were size fractionated by electrophoresis for 60 min at 25 mA and transferred to 162 
nitrocellulose membranes for western blot analysis. Images were acquired, and densitometry of 163 
the bands was performed using Quantity One software (version 4.6.9; Bio-Rad Laboratories Srl). 164 
Densitometry values were normalized using the corresponding loading controls. 165 
 166 
Quantitative nucleic acid analysis.  167 
Real-time quantitative reverse transcription (qRT)-PCR analysis was performed on a 168 
CFX96tm Real Time System (Bio-Rad Laboratories Srl). Total RNA was extracted using TRI 169 
Reagent (Sigma-Aldrich), and 1 μg was retrotranscribed using iScript cDNA Synthesis kit (Bio-170 
Rad Laboratories Srl). Reverse-transcribed cDNAs were amplified in duplicate using 171 
SsoAdvanced Universal SYBR green Supermix (Bio-Rad Laboratories Srl) for viral genes, as 172 
well as cellular genes. The glucuronidase beta (GUSB) housekeeping gene was used to 173 
normalize for variations in cDNA levels.  174 
 Total cellular DNA was isolated with QIAamp DNA Mini kit (Qiagen). A 600 ng DNA 175 
sample was digested with DpnI to remove the unreplicated input DNA. After digestion, 40 ng 176 
were analyzed by quantitative PCR (qPCR) using 500 nM primers and SsoAdvanced Universal 177 
SYBR green Supermix (Bio-Rad Laboratories Srl). The reaction conditions consisted of a 30 s 178 
95°C enzyme activation cycle, 40 cycles of 10 s denaturation at 95°C, and 10 s annealing at 179 
60°C. Copy number analysis was completed by comparing the unknown samples to standard 180 
curves of linearized HPV18 DNA. The glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 181 
DNA copy number was used as an endogenous control. The specificity of the L2 primers was 182 
tested in nontransfected cells where no amplification occurred. The primer sequences are 183 
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detailed in Supplemental Table 1. 184 
 185 
ELISA and ELISA-based transcription factor assay.  186 
The cytokines secreted in culture supernatants were analyzed using Single Analyte 187 
Human ELISA kits for IFN-β (41410; VeriKinetm Human IFN Beta ELISA KIT, PBL Assay 188 
Science) and IFN-λ1 (DY7246; DuoSet ELISA Human IL-29/IFN-λ1 R&D Systems) according 189 
to the manufacturer’s instructions. All absorbance readings were measured at 450 nM using a 190 
Victor X4 Multilabel Plate Reader (Perkin Elmer). 191 
 Nuclear extracts were prepared using NE-PER Nuclear and Cytoplasmic Extraction 192 
Reagent (78883; Thermo Fisher Scientific) according to the manufacturer’s instructions. IRFs 193 
binding activity to IFN-β and λ1 enhancers, was measured by Universal Transcription Factor 194 
Assay Colorimetric kit (70501; Merck Millipore) according to the manufacturer’s instructions. In 195 
brief, 200 ng biotin-labeled oligonucleotides containing the consensus sequence for the specific 196 
transcription factor under study were mixed with nuclear extract into each well of a streptavidin-197 
coated microtiter plate. The bound transcription factor was detected with a specific primary 198 
antibody: anti-IRF1 (sc-497X; Santa Cruz, diluted 1:400), anti-IRF3 (sc-9082X; Santa Cruz, 199 
diluted 1:400), anti-IRF7 (sc-9083X; Santa Cruz, diluted 1:200). An HRP-conjugated antibody 200 
was then used for detection with TMB substrate. The intensity of the reaction was measured at 201 
450nM using a Victor X4 Multilabel Plate Reader. The biotinylated oligonucleotides used were: 202 
IFN-β enhancer probe sense 5’- biotin 203 
ATGACATAGGAAAACTGAAAGGGAGAAGTGAAAGTGGGAAATCCTCTG- 3’ and IFN-204 
β enhancer probe antisense 5’-205 
CAGAGGAATTTCCCACTTTCACTTCTCCCTTTCAGTTTTCCTATGTCAT- 3’, IFN-λ1 206 
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enhancer probe sense 5’- biotin 207 
AGGGAGTTCTAAGGATTTCAGTTTCTCTTTCCTTCTTGATGCAGCTCCCA- 3’ and IFN-208 
λ1 enhancer probe antisense 5’-209 
TGGGAGCTGCATCAAGAAGGAAAGAGAAACTGAAATCCTTAGAACTCCCT-3’ 210 
 211 
Southern blot analysis.  212 
Southern blot analysis was performed as described previously (36). In brief, genomic 213 
DNA (10 μg) was digested with DpnI to remove any residual input DNA and with HindIII, 214 
which has no restriction site in HPV18, or EcoRI, which has two restriction sites in HPV18 215 
minicircles. The digested DNA was the separated on a 0.8% agarose gel, blotted, and hybridized 216 
with an HPV18 genome sequence-specific probe labeled with [α-32P]dCTP using Ready-To-Go 217 
DNA Labeling. The results were quantitated using a Personal Molecular Imager (PM) System 218 
(Bio-Rad Laboratories Srl) equipped with Quantity One software. 219 
 220 
FISH, immunofluorescence and immunohistochemistry analysis.  221 
Five μm sections obtained from NIKSmcHPV18 organotypic raft cultures were processed 222 
for immunofluorescent analysis and DNA-fluorescent in situ hybridization (FISH), as previously 223 
described (41). The following antibodies were used: anti-MCM7 (CDC47, MS-862-P; Neo 224 
Markers, diluted 1:200), anti-p16 (clone E6H4) was obtained from Ventana Medical System, 225 
anti-HPV α-genus E4 protein (namely PanHPVE4). FISH probe was generated by using a Biotin 226 
Nick Translation Mix (Roche Diagnostics SpA) according to the manufacturer’s protocol with 227 
the HPV18 minicircle genome as a template. Images were acquired using a digital scanner 228 
(Pannoramic MIDI; 3D Histech Kft.). For the assessment of histological features, the slides 229 
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analyzed by HPV18 E4, MCM7 or HPV18 DNA were disassembled and stained with 230 
hematoxylin and eosin (H&E). 231 
 232 
ChIP assay.  233 
ChIP assays were performed as previously described (36). Immunoprecipitation was 234 
performed with 3 µg of unmodified histone H3 (06-755), dimethyl-histone H3 (Lys4; 07-030) 235 
and dimethyl-histone H3 (Lys9; 07-441) antibodies, all purchased from Merck Millipore (Merck 236 
Millipore SpA). Threshold cycle (CT) values for the samples were equated to input CT values to 237 
give percentages of input for comparison and these were normalized to the enrichment level of 238 
unmodified histone H3 for each cell line. The primers used to amplify STING, cGAS, and RIG-I 239 
promoters are detailed in Supplemental Table 1. 240 
 241 
Statistical analysis.  242 
All statistical tests were performed using Graph-Pad Prism version 5.00 for Windows 243 
(GraphPad Software). The data are presented as mean ± standard deviation (SD). For 244 
comparisons consisting of two groups, means were compared using two tailed Student’s t tests; 245 
for comparisons consisting of three groups, means were compared using one-way or two-way 246 
analysis of variance (ANOVA) with Bonferroni’s post test. Differences were considered 247 
statistically significant at a P value of < 0.05. 248 
 249 
 250 
 251 
  252 
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Results 253 
HPV18 replication fails to induce antiviral or pro-inflammatory cytokines and inhibits DNA 254 
ligand-mediated production of type I and III IFNs. 255 
 First, we asked whether HPV18 replication per se would induce an antiviral response in 256 
KCs. For this purpose, we generated a human KC cell line, named NIKSminicircleHPV18, 257 
abbreviated as NIKSmcHPV18, stably harboring high viral load of HPV18 episomal genomes 258 
(37, 42). These cells were cultured as pooled cells and used throughout the study at passages 259 
between 20 and 30. NIKSmcHPV18 cells maintained episomal HPV18, as assessed by the 260 
representative Southern blot analysis shown in Fig. 1A. The slower migrating bands seen in the 261 
DNA sample digested with the non-cutter restriction enzyme Hind III indicate the presence of 262 
concatamers (Fig. 1A). As expected for episomal harboring cells, NIKSmcHPV18 cells formed 263 
low squamous intraepithelial lesions (L-SILs) in organotypic raft cultures, as determined by 264 
enhanced expression levels of the cellular proliferation marker minichromosome mainteinance-7 265 
(MCM7) in the suprabasal layers where E4 expression was also well evident (Fig. 1B) (43). 266 
Viral load was measured by qPCR of total genomic DNA at various passages along with the 267 
quantification of viral transcription from total RNA extracts. We measured mRNA expression 268 
levels of E6, E7, and E2 oncogenes, with the latter being a specific marker of episome-derived 269 
transcription. As shown in Fig. 1C, the viral load ranged from 200 to 60 copies per cell. 270 
Furthermore, cells cultured from passage 20 expressed much higher levels of E6 and E7 mRNA 271 
than those of E2 (Fig. 1D). Consistent with this viral mRNA expression pattern, cells were found 272 
negative for p53 protein expression (data not shown). Despite the variations observed in viral 273 
load and viral mRNA expression levels, both Southern blotting pattern and L-SIL phenotype 274 
remained unchanged between passages 20 and 30 and the results described onwards were 275 
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performed at different passages with reproducible results.  276 
Next, we measured mRNA expression levels of both type I and III IFN genes along with 277 
those of some pro-inflammatory cytokines in both NIKSmcHPV18 and NIKS cells. All IFN 278 
mRNAs, with the exception of IFN-α, were significantly downregulated in NIKSmcHPV18 cells 279 
when compared to parental cells (Fig. 2A). Intriguingly, we observed a significant upregulation 280 
of the IL-6 gene product, while the other cytokines were only marginally affected.  281 
 To obtain a cell model that would more closely recapitulate the natural replication of 282 
HPV, we generated organotypic raft cultures using both NIKS and NIKSmcHPV18 cells and 283 
measured the mRNA expression levels of the same panel of genes described above. As shown in 284 
Fig. 2B, both type I and III IFN mRNA levels were significantly downregulated in 285 
NIKSmcHPV18 cells when compared to those of parental cells, indicating that HPV-mediated 286 
escape from the immune response correlates with inhibition of IFN gene expression. IL-18 287 
mRNA expression levels were also significantly downregulated, whereas those of IL-6 and IL-8 288 
were significantly upregulated.  289 
 We next asked whether NIKSmcHPV18 cells were still able to react to exogenous DNA 290 
ligands in terms of type I and III IFN production. Since the physical status of the virus, episomal 291 
or integrated, may generate variability in the innate immune response of epithelial cells, we also 292 
included in our analysis HeLa cells harboring an integrated HPV18 DNA (44, 45). Cells cultured 293 
between 20 and 30 passages were transfected with SS DNA or the viral dsDNA analogue 294 
poly(dA:dT), and then total RNAs were isolated from cells at the 12 h time point, while their 295 
supernatants were collected after 24 h of treatment to allow enough time for lymphokines to 296 
accumulate in the medium. Transfection of NIKS with either poly(dA:dT) or SS DNA increased 297 
mRNA expression levels of all IFNs tested, with IFN-β and IFN-λ1 being the highest induced 298 
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genes (Fig. 3A); in all cases, SS DNA was a less potent inducer than poly(dA:dT). Remarkably, 299 
in both NIKSmcHPV18 and HeLa cells, DNA ligand-mediated induction of all IFN genes tested 300 
was dramatically reduced compared to NIKS cells (Fig. 3A).  301 
Next, we assessed the extent of IFN-β and IFN-λ1 production at the protein level by 302 
ELISA. Consistent with the mRNA levels, IFN-β production in poly(dA:dT)- or SSDNA-303 
transfected NIKSmcHPV18 cells was markedly downregulated compared to control cells (i.e. 304 
80% and 83 reduction, respectively), while it was barely detectable in HeLa cells (Fig. 3B). 305 
Likewise, DNA ligand-mediated IFN-λ1 production was significantly inhibited in either cell 306 
types compared to control cells [e.g. 68% and 46% reduction in NIKSmcHPV18 cells, and 89 307 
and 98% in HeLa cells transfected with either poly(dA:dT) or SS DNA, respectively] .   308 
Lastly, in good agreement with previous findings showing hyperactivation of NF-κB 309 
transcriptional activity in KCs overexpressing hrHPVE6 and E7 (46-48), we found that 310 
NIKSmcHPV18 and HeLa cells transfected with DNA ligands displayed increased expression of 311 
IL-6, an NF-κB downstream target gene, at both the mRNA and protein levels (Fig. 3A and C, 312 
respectively) compared to control cells.  313 
Altogether, these findings clearly indicate that: i) episomal HPV18 does not induce an 314 
antiviral innate immune response; ii) KCs carrying episomal HPV18 as well as HeLa cells poorly 315 
respond to exogenous DNA ligands in terms of both type I and III IFN production compared to 316 
parental cells; and iii) the HPV18 inhibitory activity does not seem to affect NF-κB function.  317 
 318 
Dysregulation of the innate immune response in HPV18-positive keratinocytes is characterized 319 
by specific alterations in antiviral innate signaling pathways.  320 
To gain more insights into the molecular mechanisms of HPV18-mediated regulation of 321 
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type I and III IFN expression levels in NIKSmcHPV18 cells and HeLa cells, we measured by 322 
Western blot protein levels of various PRRs (i.e. cGAS, RIG-I, and IFI16), the adaptor 323 
molecules STING and MAVS, as well as the transcription factors IRF1, 3 and 7. Fig. 4A 324 
illustrates the schematic representation of the pathways involved in the innate immune response 325 
to exogenous DNA. cGAS, STING, RIG-I, and IFI16 were all very low in both untreated 326 
NIKSmcHPV18 and HeLa cells compared to NIKS cells, while MAVS did not vary significantly 327 
(Fig. 4B and C). When we transfected these cells with poly(dA:dT) for 24 h, we observed a 328 
slight increase in cGAS expression in NIKS cells but not in NIKSmcHPV18 and HeLa cells. 329 
IFI16 displayed a dual expression pattern. While it was downregulated in poly(dA:dT)-330 
transfected NIKS cells, it was significantly upregulated in both NIKSmcHPV18 and HeLa cells 331 
similarly treated. RIG-I induction by poly(dA:dT) was observed in both KCs carrying episomal 332 
HPV18 and NIKS. As expected, STING expression levels were reduced after poly(dA:dT) 333 
transfection in NIKS cells, while they remained barely detectable in HPV-infected cells (49).  334 
A recent report has shown that E7 is a potent and specific inhibitor of the cGAS-STING 335 
pathway, thereby hampering type I IFN production by DNA ligands in HeLa cells (17). While 336 
not reported in that study, here we found that both STING and cGAS are barely detectable or 337 
absent in NIKSmcHPV18 and HeLa cells (Fig. 4B and C), suggesting that one of the possible 338 
mechanism by which HPV18 keeps antiviral factors in check is through downregulation of 339 
STING expression.  340 
When we measured the expression of IRF1, 7, and 3 proteins (Fig. 4D to G), we made the 341 
following observations: i) IRF1, which was barely detectable in all untreated cells, was strongly 342 
induced in both poly(dA:dT)-transfected NIKS and HeLa cells but not NIKSmcHPV18 cells, 343 
reaching a peak in both cases at the 24 h time point; ii) IRF7 expression, which was very low in 344 
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untreated NIKS cells, was strongly induced upon poly(dA:dT) transfection with a peak at the 12 345 
h time point. In contrast, IRF7 induction by poly(dA:dT) was completely ablated in HeLa cells 346 
and strongly delayed in NIKSmcHPV18, where it became evident only at the 24 h time point; iii) 347 
IRF3 protein expression, which was readily detectable in all untreated cells, did not vary 348 
following poly(dA:dT) transfection (Fig. 4F and G). We also observed IRF3 dimerization after 349 
poly(dA:dT) transfection in all cell lines, although in KCs harboring episomal HPV18 dimer 350 
formation was slower compared to NIKS cells (Fig. 4H and I). 351 
Thus, it seems that the defects in type I and III IFN production observed in 352 
NIKSmcHPV18 cells after poly(dA:dT) transfection may be ascribed to multiple abnormalities 353 
in antiviral innate signaling pathways. In particular, the reduced availability of cGAS, STING, 354 
RIG-I, and IFI16 in HPV-infected cells, together with the lack of induction of IRF1 and IRF7, 355 
might provide the rationale for HPV18 immune evasion after DNA ligand stimulation. 356 
 357 
The RIG-I-MAVS pathway is restored upon poly(dA:dT) transfection in HPV18-positive cells, 358 
while the cGAS-STING pathway remains inhibited.  359 
Since poly(dA:dT) transfection was shown to be able to induce IFN-β even in cells void 360 
of cGAS and STING (50), we asked whether downregulation of the polymerase III-RIG-I-361 
MAVS signaling pathway activity by HPV could partly explain our observation that this 362 
stimulus failed to induce both type I and III IFN production in NIKSmcHPV18 and HeLa cells, 363 
but not NIKS cells. To this end, we first looked at RIG-I mRNA expression levels in either mock 364 
or poly(dA:dT)-transfected cells at different time points. Consistent with our previous data (Fig. 365 
4B and C), basal RIG-I mRNA levels were reduced in both NIKSmcHPV18 and HeLa cells 366 
compared to NIKS cells (20% and 98%, respectively) (Fig. 5A). Upon poly(dA:dT) transfection, 367 
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RIG-I mRNA was quickly induced in NIKS cells at 3 h, reaching a peak at 12 h, while in HPV-368 
positive cells RIG-I started to increase only at the 6 h time point, albeit to a lesser extent 369 
throughout the time course. The same delayed kinetics was observed at the protein level, where 370 
the protein became more evident after 6 h in HPV-positive cells, while it was induced at the 3 h 371 
time point in parental cells (Fig. 5B). This delay in RIG-I induction in HPV-positive cells might 372 
also explain the delayed formation of IRF3 homodimers occurring in these cells after 373 
poly(dA:dT) stimulation (Fig. 4H and I). When we measured IFNs in the supernatants, we found 374 
them quickly released in NIKS cells—IFN-β at 6 h and IFN-λ1 at 12 h—while in HPV-positive 375 
cells they were both induced at 12 and 24 h, respectively (Fig. 5C).  376 
Next, we asked whether the RIG-I-MAVS pathway mediated IFN induction in response 377 
to poly(dA:dT) transfection. To this end, we inhibited MAVS with the protonophore carbonyl 378 
cyanide m-chlorophenylhydrazone (CCCP), which is capable of ablating RLR signaling through 379 
disruption of mitochondrial integrity (51). Consistent with a previous report (52), CCCP-treated 380 
NIKS cells remained viable and metabolically active throughout the 2-day-long experiment (data 381 
not shown). As expected, poly(dA:dT)-induced IFN-β and IFN-λ1 production was markedly 382 
reduced in both NIKSmcHPV18 and HeLa cells compared to that of NIKS cells (Fig. 5C and D). 383 
CCCP treatment of NIKS cells led to a 2.5-fold decrease in both IFN-β and IFN-λ1 production, 384 
which nevertheless remained much higher than DMSO-treated NIKSmcHPV18 and HeLa cells 385 
(Fig. 5D). Likewise, CCCP treatment of poly(dA:dT)-transfected NIKSmcHPV18 cells 386 
downregulated IFN-β and IFN-λ1 of about 1.5-fold and 1.8-fold, respectively compared to 387 
DMSO-treated NIKSmcHPV18 cells. IFN-λ1 production was also reduced in HeLa cells of about 388 
2.6-fold compared to DMSO-treated cells, while levels of IFN-β remained constantly low. Thus, 389 
in HPV-positive cells, where the STING pathway is apparently turned off, the amount of IFN 390 
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produced upon poly(dA:dT) treatment seems to be mainly mediated by the RIG-I-MAVS 391 
pathway. Furthermore, the delayed kinetics of IFN production in these cells might be due to the 392 
unavailability of RIG-I under basal conditions. Lastly, reduced RIG-I mRNA levels in untreated 393 
HPV-positive cells suggests that HPV acts as a RIG-I transcriptional repressor able to dampen 394 
the innate antiviral response during persistent infection. Likewise, basal mRNA levels of both 395 
cGAS and STING were significantly lower than those seen in parental cells [i.e. 60% and 90% 396 
for cGAS and STING in NIKSmcHPV18 cells, and 64% and 65% in HeLa cells, respectively 397 
(Fig. S1)].  398 
Recent evidence indicates that STING transcriptional regulation is mediated by STAT1 399 
binding (53, 54). In addition, STAT1 transcriptional activity was markedly inhibited in hrHPV-400 
infected KCs (55), thus providing a possible mechanistic framework by which HPVs 401 
downregulate STING in host cells. We therefore assessed STAT1 expression at both the mRNA 402 
and protein level at baseline or after poly(dA:dT) transfection as described above. In good 403 
agreement with previous findings, STAT1 mRNA basal levels in HPV-positive cells were 404 
reduced by 52% in NIKSmcHPV18 and 92% in HeLa compared to NIKS cells. Furthermore, 405 
STAT1 expression was induced in all cell lines following poly(dA:dT)  transfection, albeit to a 406 
much lesser extent in HPV-positive cells—approximately 80% less than parental cells at the 12 h 407 
time point (Fig. 6A). Consistent with the mRNA induction kinetics, both total and 408 
phosphorylated STAT1 protein levels increased upon poly(dA:dT) transfection in HPV-positive 409 
cells with a delay of 6 and 12 h in NIKSmcHPV18 and HeLa cells, respectively (Fig. 6B). 410 
To confirm that the downregulation of these proteins by HPV18 was occurring at the 411 
transcriptional level, we treated cells with the proteasome inhibitor MG132 for 8 h, and then 412 
assessed protein levels of various PRRs and adaptor molecules as described above. Even though 413 
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the drug induced accumulation of ubiquitylated proteins, it did not promote any accumulation of 414 
the proteins analyzed (Fig. 6C). 415 
 Thus, our results indicate that viral immune escape in HPV-positive cells is due to 416 
constitutive downregulation of at least two important cytoplasmic PRRs, cGAS and RIG-I, and 417 
the adaptor protein STING. Furthermore, low levels of STAT1 factor may explain why STING 418 
basal expression is reduced in HPV-positive cells.  419 
 420 
HPV18 promotes heterochromatin association with the promoter region of STING, cGAS, and 421 
RIG-I genes. 422 
 Broad regulation of the transcriptional competence of host cell chromatin has been 423 
previously reported in HPV-infected cells (56-59). To verify whether the transcriptional 424 
inhibition of the cGAS, STING, and RIG-I genes observed in HPV-positive cells could also 425 
reflect changes in chromatin structure, we examined histone associations whit the promoter 426 
region of the above mentioned genes in HPV-positive vs. parental cells by ChIP assay. For this 427 
experiment, we chose dimethylation of histone H3 lysine 4 (H3K4me2) as a mark of actively 428 
transcribing genes, and dimethylation of histone H3 lysine 9 (H3K9me2) as a mark of 429 
heterochromatin. We then performed ChIP assay using lysates from formaldehyde-fixed 430 
NIKSmcHPV18, HeLa, and NIKS cells, and two sets of PCR primers that could specifically 431 
amplify the promoter regions of the STING, cGAS, and RIG-I genes. The first primer set 432 
encompassed the promoter region where the putative STAT1 binding site is located (segment 1), 433 
while the second set was directed to a flanking region always within the promoter that included 434 
the transcription start site (TSS), which, in the case of cGAS, also included the putative 435 
interferon-sensitive response element (ISRE) binding site (segment 2) (Fig. 7A). As shown in 436 
 20
Fig. 7B, HPV18 had little or no effect on the association of H3K4me2 (active chromatin) with 437 
either segment 1 or 2 in all three promoters. In contrast, we observed a significant increase in 438 
H3K9me2 (repressive chromatin) bound to the two segments in all promoters from lysates of 439 
HPV-positive vs. NIKS cells. Interestingly, dimethylated H3K9me2 binding levels to the three 440 
promoter regions in NIKSmcHPV18 were 5- to 15-fold higher than those seen in NIKS cells for 441 
both segments. In HeLa cells, we detected even higher H3K9me2 binding levels to segments 1 442 
and 2 of the same promoter regions than those observed in NIKSmcHPV18 cells. The levels of 443 
H3K9me2 and H3K4me2 bound to gene segments located far away from the promoter region 444 
were comparable in all three cell lines as well as in the GAPDH promoter region (Fig. S2). Thus, 445 
HPV18 represses STING, cGAS, and RIG-I gene expression by promoting heterochromatin 446 
association with their promoter regions.   447 
 448 
The binding activity of IRF1 and 7 but not IRF3 to the IFN enhancer is reduced in HPV-infected 449 
cells.  450 
Since IRF family members displayed different temporal protein profiles in HPV-positive 451 
vs. parental cells upon DNA ligand stimulation (Fig. 4D and E), and we detected concomitant 452 
induction of IRF3 homodimer formation (Fig. 4H and I), albeit significantly delayed in HPV-453 
expressing cells, we sought to determine whether IRF species were transcriptionally active in 454 
these cells. For this purpose, we performed a sensitive quantitative ELISA-based assay using a 455 
biotin-labeled probe that spanned the tandem IRF binding sites present in either the IFN-β or 456 
IFN- λ1 enhancer (Fig. 8A). Since identical results were obtained with both probes, only the set 457 
of panels for IFN-β is shown in Fig. 8B. IRF1, 3, and 7 all bound very efficiently to the 458 
immobilized probes in poly(dA:dT)-transfected NIKS cells, and their binding kinetics mirrored 459 
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the changes in protein expression. Specifically, IRF1 binding activity was readily induced in 460 
both poly(dA:dT)-transfected NIKS and HeLa cells (Fig. 8B), in a fashion consistent with the 461 
changes in protein expression (Fig. 4D and E). In contrast, NIKSmcHPV18 cells displayed low 462 
basal IRF1 binding activity, which remained basically unchanged throughout the entire time 463 
course following poly(dA:dT) transfection, in good agreement with the protein expression 464 
kinetics shown in Fig. 4D and E. On the other hand, induction of IRF3 binding activity by 465 
poly(dA:dT) was readily detectable at the 3 h time point and did not differ among cell lines (Fig. 466 
8B). Lastly, induction of IRF7 binding activity was observed only after 12 h of poly(dA:dT) 467 
transfection of NIKS cells, whereas it was inhibited in both NIKSmcHPV18 and HeLa cells 468 
similarly treated, mirroring the protein expression kinetics shown in Fig. 4D and E. Thus, it 469 
appears that HPV can interfere with IRF DNA binding activity following DNA ligand-470 
stimulation in a cell type-specific fashion, thereby hampering the innate immune response in 471 
these cells. 472 
 473 
 474 
 475 
 476 
 477 
 478 
 479 
 480 
 481 
 482 
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Discussion 483 
Escape from innate immune surveillance appears to be the hallmark of HPV infections (6, 484 
7, 60). Although some mechanisms of immune evasion by HPVs, especially HPV16, have been 485 
previously characterized, they were mostly based on results obtained from either KCs 486 
overexpressing only E6 and E7 or non-epithelial cells, thereby hampering data interpretation (17-487 
21).  488 
Here, in order to better recapitulate the HPV impact on its natural target cells (i.e. KCs), 489 
we have assessed the innate immune response in NIKSmcHPV18 cells, which are KCs carrying 490 
high numbers of episomal viral genome copies. These cells were used at passages between 20 491 
and 30, when the E6 and E7 transcripts were higher than those of E2, an expression pattern 492 
typical of persistent HPV infection. For comparison, we also included HeLa cells, which are 493 
cervical carcinoma-derived transformed cells harboring integrated HPV18 genomic DNA 494 
characterized by deregulated overexpression of E6 and E7 oncogenes (44,45). We then used 495 
these cells to determine how persistent infection with HPV would affect their response to 496 
exogenous DNA.  497 
Our findings demonstrate that KCs can maintain high copy number of episomal viral 498 
DNA without triggering an antiviral response because multiple points of the molecular pathways 499 
involved in the induction of both type I and III IFNs are being inhibited. In this regard, we failed 500 
to detect any IFN production in KCs grown either in monolayer or under differentiating 501 
conditions using organotypic raft cultures. Consistent with other reports, the NF-κB dependent 502 
gene IL-6 was upregulated at higher levels in HPV-positive cells compared to parental cells, 503 
indicating that the NF-κB pathway was functionally active in KCs carrying episomal HPV18 as 504 
well as HeLa (46-48). 505 
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 When we stimulated NIKSmcHPV18 with DNA ligands, we found that induction of both 506 
IFN-β and IFN-λ1 were significantly reduced compared to parental cells. Remarkably, cGAS, 507 
STING, RIG-I and IFI16 proteins were all poorly expressed or almost undetectable in 508 
NIKSmcHPV18 cells when compared to parental NIKS cells. Their suppression mainly occurred 509 
at the mRNA rather than the protein level. The observed increase in repressive heterochromatin 510 
markers at the promoter region of STING, cGAS, and RIG-I genes argues in favor of epigenetic 511 
silencing of these genes as a mechanism to stably repress key components of the innate antiviral 512 
response against DNA viruses.  513 
Thus, altogether, our findings support a model whereby reduced expression of PRRs in 514 
HPV-positive cells, along with that of the adaptor protein STING (61), which bridges most DNA 515 
receptors to downstream signaling events, create an unreactive cellular milieu suitable for viral 516 
persistence, replication and tumorigenesis (Fig. 9). In support of this model, human 517 
osteosarcoma U2OS cells, which are highly permissive to HPV replication, display a series of 518 
defects in innate immunity, including the absence of cGAS and STING proteins (37, 42, 62, and 519 
unpublished personal data). As all these proteins are considered to be IFN-stimulated genes 520 
(ISGs), our findings are consistent with previous reports demonstrating that hrHPV genotypes 521 
inhibit a number of ISGs at the transcriptional level (22, 58, 63-65). However, these mechanisms 522 
differ from the evasion strategies reported for many other viruses that usually target PRRs and 523 
downstream molecules through post-translational modifications leading to increased protein 524 
degradation and temporary shutdown of the signaling cascade (66-69). These events usually take 525 
place at the early stages of infection. This discrepancy can be easily explained by the fact that we 526 
are dealing with a virus that displays an unusual life cycle, as it does not cause lytic infection, but 527 
rather has evolved strategies to remain inside the cells for a very long time, can replicate without 528 
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being recognized by innate sensors, and eventually promotes tumorigenesis (70). Thus, in our 529 
model of viral persistence, it is not unexpected that we found alternative strategies used by these 530 
viruses to keep the guardians in a prolonged inactive state. This inhibitory activity seems to be 531 
irreversible in the case of the cGAS-STING pathway, as we did not find any recovery of these 532 
proteins even after treatment with exogenous DNA, while RIG-I protein expression was induced 533 
in response to poly(dA:dT) transfection and likely mediated the residual IFN production 534 
observed in both HPV-positive cells (Fig. 9). Indeed, when we exposed poly(dA:dT) transfected 535 
HPV-positive cells to the protonophore CCCP, a known disruptor of RIG-I-MAVS signaling 536 
(51,52), both type I and III IFN levels in the supernatants were dramatically reduced. 537 
Furthermore, RIG-I upregulation was delayed in HPV-positive cells and accompanied by the 538 
induction of IFNs, indicating that this pathway could be restored and was responsible for the 539 
delayed antiviral response. Intriguingly, we found the same pattern of PRR inhibition and 540 
epigenetic modifications in NIKSmcHPV18 and HeLa cells, indicating that the evasion strategies 541 
are put in place at early stages of cancer progression and maintained over time even when the 542 
virus is fully integrated into the human genome, as in the case of HeLa cells.  543 
Frequent suppression of cGAS and STING expression has been indeed observed in many 544 
types of human cancer, suggesting that this pathway may play a major role in suppressing 545 
tumorigenesis, and that its selective inhibition may occur frequently in viral-induced cancers 546 
(71,72). In this regard, the cGAS-STING pathway is crucial in triggering a potent down-stream 547 
interferon response against cytosolic DNA often present in cancer cells (73). Thus, inhibition of 548 
this signaling pathway by HPV18 is consistent with a model whereby infected cells escape the 549 
attention of the immune surveillance system, acquire further genetic mutations and eventually 550 
become transformed. The observed inhibition of cGAS-STING signaling may also help clarify 551 
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why cells harboring hrHPV infection do replicate despite the activation of the DNA damage 552 
response (DDR), which ordinarily arrests cellular replication also through activation of the innate 553 
response (74). 554 
Although RIG-I was originally identified as a crucial cytoplasmic PRR for the 555 
recognition of many negative-strand RNA viruses, mounting evidence indicates that it also plays 556 
a role in detecting several DNA viruses [e.g. Epstein-Barr virus (EBV), Kaposi sarcoma-557 
associated herpesvirus (KSHV), herpes simplex virus 1 (HSV-1), and adenoviruses], and in some 558 
cases it can recognize RNA species generated by RNA polymerase III, thus explaining the 559 
observed inhibition in HPV-infected cells reported here (32, 33, 75, 76).  560 
In recent years, several intracellular DNA sensor candidates have been identified. Most of 561 
them appear to function through the essential adaptor protein, STING (11, 14, 66, 67). Although 562 
the functional relevance of some of these DNA sensors still needs to be fully established, cGAS 563 
and IFI16 have been identified as bona fide intracellular viral DNA receptors (77). Here we 564 
demonstrate that, in KCs stably maintaining episomal viral DNA, cGAS and STING expression 565 
levels are very low and are not induced by poly(dA:dT). Thus, the lack of the universal adaptor 566 
protein STING per se is sufficient to explain the absence of IFN induction during HPV infection, 567 
even though which DNA sensor is engaged by HPV still remains to be defined. The IFI16 568 
protein is a viral DNA sensor that could be a potential candidate for binding and recognition of 569 
the HPV DNA (78). Unfortunately, and despite many efforts, we have failed to demonstrate any 570 
IFI16-HPV DNA interaction (36 and unpublished personal data). However, we found that IFI16 571 
is downregulated under basal conditions in HPV-positive cells as a mechanism to attenuate its 572 
activity as either DNA sensor or restriction factor (79).  573 
When we turned our attention to the down-stream transcriptional factors activated by the 574 
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cGAS-STING and RIG-I-MAVS pathways, we made a series of interesting observations that 575 
helped us further elucidate the complex modulation of these pathways during HPV infection. 576 
While IRF3 protein levels were only marginally decreased by the presence of HPV18, both IRF1 577 
and, albeit to a lesser extent, IRF7 were reduced in NIKSmcHPV18 cells. Consistent with the 578 
reduced availability of the IRF1 and IRF7 proteins, their binding activities to the consensus 579 
binding sites present in both β and λ1 IFN enhancers were significantly reduced. In HeLa cells, 580 
IRF7 protein expression was almost undetectable, and it was not induced by DNA ligands, while 581 
IRF1 protein expression levels were less affected. According to the notion that IRF7 is a crucial 582 
factor for IFN-β production, the induction of IRF7 by DNA ligand was robust in NIKS cells, 583 
whereas it was strongly reduced and delayed in NIKSmcHPV18 cells and completely ablated in 584 
HeLa cells (80-82).  585 
A partial limitation of our study is that we are not providing definitive mechanistic details 586 
underlying the defects in the innate antiviral system observed in HPV-positive cells. Further 587 
studies are therefore clearly needed to clarify, for example, how the oncoproteins E6 and E7 or 588 
other early genes contribute to this inhibition. Despite this limitation, one of the strengths of this 589 
study is represented by the establishment of a reliable cell model where KCs stably harbor the 590 
entire viral genome, thereby closely recapitulating persistent HPV infection. Of note, similar 591 
results were also obtained with HeLa cells, which are known to contain integrated HPV18 DNA. 592 
In addition, our findings provide valuable information about innate immunity in KCs, which is a 593 
process still poorly characterized despite the fundamental role played by these cells not only in 594 
providing a physical barrier against infection and environmental insults, but also in sensing viral 595 
pathogens, thereby initiating and shaping local immune responses. 596 
Overall, our findings provide compelling evidence that HPV persistence in KCs leads to 597 
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the inhibition of not only type I IFN but also type III IFN production in response to DNA 598 
ligands, and that this effect is mainly due to the suppression of cGAS-STING signaling. As 599 
stated above, deregulation of STING signaling in cells with persistent hrHPV infection can 600 
hamper DDR, thereby enabling infected cells to evade host immunosurveillance and eventually 601 
become tumorigenic.  602 
The fact that we employed HPV-infected cells harboring the entire genome could explain 603 
some inconsistencies between our results and those of others. In this regard, Lau and co-workers 604 
have recently shown that E7 binds and degrades STING, thereby antagonizing the cGAS-STING 605 
DNA-sensing pathway (17). Our data imply that inhibition of STING activity occurs mainly at 606 
the transcriptional rather than post-transcriptional level. However, based on our data, we cannot 607 
rule out that both mechanisms might be involved.  608 
In summary, a series of reports dating back to the first decade of the 2000s, clearly 609 
documented that hrHPV can inhibit several ISG transcripts mainly through E6 and E7 (22, 58, 610 
63-65). In this study, we provide new evidence that the inhibitory action of HPV18 also affects 611 
some ISGs crucial for the innate antiviral response such as PRRs and IRFs. In addition, 612 
production of both IFN-β and IFN-λ1 in response to poly(dA:dT) transfection was also impaired 613 
in CaSki cells harboring integrated HPV16 (data not shown) through inhibition of cGAS-STING 614 
signaling. Thus, our findings indicate that hrHPV genotypes have evolved broad-spectrum 615 
mechanisms that allow simultaneous depletion of multiple effectors of the innate immunity 616 
network rather than single downstream effectors.  617 
These novel mechanistic insights into HPV immune evasion are critical for understanding 618 
how HPV can persistently infect steadily unreactive cells and promote cancer. 619 
 620 
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Figures Legends 1027 
FIGURE 1. Characterization of NIKSmcHPV18. (A) Total DNA extracts from NIKSmcHPV18 1028 
(lane 4 and 5) were prepared for Southern blot analysis. For all samples, genomic DNA (10 μg) 1029 
was digested with either HindIII (lane 4) or EcoRI (lane 5)—HPV18 minicircles do not have any 1030 
HindIII restriction sites, while they contain one EcoRI site in the HPV genome and one in the 1031 
linker, which give rise to two bands of 5,113 bp and 2,835 bp, respectively (lane 5). Standards of 1032 
HPV18 minicircles digested with EcoRI corresponding to 10,000, 1,000, and 100 copies of the 1033 
HPV18 genome per cell were included as internal control (lanes 1, 2, and 3, respectively). The 1034 
8,000-bp band corresponds to partially digested minicircle DNA. For detection of DNA, the filter 1035 
was hybridized with a complete HPV18 genomic probe. (B) Phenotype of NIKSmcHPV18 cells 1036 
in organotypic cultures. The images show histologic appearances following H&E staining, 1037 
together with the expression of the cellular marker p16INK4a and MCM7, the viral protein E4, and 1038 
the HPV18 genome as detected by fluorescent in situ hybridization (FISH), which was followed 1039 
by DAPI counterstaining to visualize cell nuclei (blue). Scale bar=100 μm. (C) To measure viral 1040 
replication, total cellular DNA was analyzed by qPCR after DpnI digestion in NIKSmcHPV18 1041 
cells at different passages. HPV18 levels were normalized to GAPDH levels. (D) qRT-PCR 1042 
analysis of relative HPV18 early gene mRNA expression levels in NIKSmcHPV18 at different 1043 
passages. Values were normalized to viral copy number and calculated using the following 1044 
formula: mean relative mRNA expression ratio/mean relative HPV18 copy number. qPCR and 1045 
qRT-PCR data are presented as mean values of biological triplicates. Error bars indicate SD. 1046 
 1047 
FIGURE 2. HPV18 harboring cells fail to produce antiviral or pro-inflammatory cytokines. (A) 1048 
Quantitative real-time PCR (qRT-PCR) analysis of mRNA expression levels in NIKS or 1049 
 47
NIKSmcHPV18 grown as monolayer cultures. Values are normalized to GUSB mRNA, and 1050 
plotted as fold induction over NIKS cells. Data are presented as mean values of biological 1051 
triplicates. Error bars indicate SD *, P<0.05; **, P<0.01, ***P< 0.001; unpaired t test compared 1052 
with NIKS monolayer. (B) qRT-PCR analysis of mRNA expression levels in NIKS or 1053 
NIKSmcHPV18 organotypic raft cultures, cultured for 16 days at the air-liquid interface. Values 1054 
were normalized to GUSB mRNA, and plotted as a fold induction over NIKS organotypic raft 1055 
cultures. Data are presented as mean values of biological triplicates. Error bars indicate SD *P< 1056 
0.05, **P< 0.01, ***P< 0.001; unpaired t-test compared with NIKS organotypic raft cultures. 1057 
 1058 
FIGURE 3. HPV18 impairs IFN-β and IFN-λ1 production by DNA ligands. (A) qRT-PCR 1059 
analysis of mRNA expression levels in NIKS, NIKSmcHPV18, and HeLa cells untransfected 1060 
(white bars), mock-transfected (light grey bars), or transfected with either 1.25 μg poly(dA:dT) 1061 
(black bars) or 1.25 μg SS DNA (dark grey bars) for 12 h. Values were normalized to GUSB 1062 
mRNA, and plotted as a fold induction over mock-transfected NIKS cells. (B) ELISA 1063 
quantitation of IFN-β and IFN-λ1 protein in supernatants from cells transfected for 24 h as 1064 
described in panel A. All qRT-PCR and ELISA data are presented as mean values of biological 1065 
triplicates. Error bars indicate SD *P< 0.05, **P< 0.01, ***P< 0.001; unpaired t-test compared 1066 
with NIKS cells untransfected, mock-transfected or transfected with either poly(dA:dT) or SS 1067 
DNA. (C) Enzyme amplified sensitivity immunoassay (EASIA) quantification of IL-6 protein in 1068 
supernatants from the cells transfected for 24 h as described in panel A. Data are presented as 1069 
mean values of biological triplicates performed with cells between 20 and 30 passages. Error 1070 
bars indicate SD *P< 0.05, **P< 0.01, ***P< 0.001; unpaired t-test compared with mock-1071 
transfected cells. 1072 
 48
 1073 
FIGURE 4. HPV18 disrupts different control points of the innate immune response in KCs. (A) 1074 
Schematic model of the PRR pathways (B) Immunoblot analysis for cGAS, STING, RIG-I, 1075 
MAVS, IFI16, and α-tubulin using total protein extracts from NIKS, NIKSmcHPV18, or HeLa 1076 
cells following 24 h transfection in the absence (-) or presence (+) of 1.25 μg poly(dA:dT). (D) 1077 
Immunoblot analysis for IRF1 and IRF7, (F) for IRF3 and (H) native gel analysis of IRF3 1078 
dimerization in total protein extracts from the cells described in A. (C, E, G and I). Densitometric 1079 
analysis showing fold-change expression of the indicated proteins from three independent 1080 
experiments. Error bars indicate SD *P< 0.05, **P< 0.01, ***P< 0.001; unpaired t-test compared 1081 
with mock-transfected NIKS. 1082 
 1083 
FIGURE 5. RIG-I delayed induction mediates the residual IFN-β and IFN-λ1 production in 1084 
HPV18 harboring cells. (A) qRT-PCR analysis of RIG-I mRNA expression levels in NIKS, 1085 
NIKSmcHPV18, and HeLa cells mock-transfected or transfected with 1.25 μg poly(dA:dT) for 1086 
the time points indicated. Values were normalized to GUSB mRNA, and plotted as fold 1087 
induction over mock-transfected NIKS cells. qRT-PCR data are presented as mean values of 1088 
biological triplicates. Error bars indicate SD *P< 0.05, **P< 0.01, ***P< 0.001; unpaired t-test 1089 
compared with NIKS cells mock-transfected or transfected with either poly(dA:dT) for 3, 6, 12 1090 
or 24 h. (B) Immunoblot analysis for RIG-I expression levels in the cells described in panel A, 1091 
and densitometric analysis showing fold-change expression from three independent experiments. 1092 
Error bars indicate SD *P< 0.05, **P< 0.01, ***P< 0.001; unpaired t-test compared with mock-1093 
transfected NIKS. 1094 
 (C) ELISA quantitation of IFN-β and IFN-λ1 protein in supernatants from the cells described in 1095 
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panel A. Data are presented as mean values of biological triplicates. Error bars indicate SD **P< 1096 
0.01, ***P< 0.001; one-way ANOVA followed by Bonferroni’s post test compared with NIKS 1097 
cells mock-transfected. (D) ELISA quantitation of IFN-β and IFN-λ1 protein in supernatants 1098 
from NIKS, NIKSmcHPV18, and HeLa cells treated with 10 μM CCCP or vehicle alone 1099 
(DMSO) for 30 min and then mock-transfected or transfected with 1.25 μg poly(dA:dT) for 24 h. 1100 
Data are presented as mean values of biological triplicates. Error bars indicate SD *P< 0.05, 1101 
**P< 0.01; unpaired t-test compared with vehicle-treated cells. 1102 
 1103 
FIGURE 6. STAT1 mRNA is transcriptionally suppressed in HPV18 harboring cells. (A) qRT-1104 
PCR analysis of STAT1 mRNA expression levels. The values were normalized to GUSB 1105 
mRNA, and plotted as a fold induction over mock-transfected NIKS cells. qRT-PCR data are 1106 
presented as mean values of biological triplicates. Error bars indicate SD *P< 0.05, **P< 0.01, 1107 
***P< 0.001; unpaired t-test compared with NIKS cells mock-transfected or transfected with 1108 
either poly(dA:dT) for 3, 6, 12 or 24 h. (B) Immunoblot analysis for STAT1 total and 1109 
phosphorylated protein  in NIKS, NIKSmcHPV18, and HeLa cells untransfected, mock-1110 
transfected or transfected with 1.25 μg poly(dA:dT) for the times indicated (left panel), and 1111 
densitometric analysis showing fold-change expression from three independent experiments 1112 
(right panel). Error bars indicate SD *P< 0.05, **P< 0.01, ***P< 0.001; unpaired t-test 1113 
compared with mock-transfected NIKS (C) Immunoblot analysis of protein extracts from NIKS, 1114 
NIKSmcHPV18, and HeLa cells treated with the proteasome inhibitor MG132 (30μM) for 8 h or 1115 
vehicle alone (DMSO). All the Western blot data are representative of at least three experiments. 1116 
 1117 
FIGURE 7. HPV18 promotes heterochromatin association at the promoter of STING, cGAS and 1118 
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RIG-I genes. (A) Depiction of the promoter region from STING, cGAS, and RIG-I genes. 1119 
Position of the primers used to assess the levels of histone binding at segment #1 and #2 is 1120 
indicated, as well as that of the putative STAT1 and ISRE consensus sequence. (HPTMs: histone 1121 
posttranslational modifications; bs: binding site; TSS: transcription start site). (B) Extracts were 1122 
prepared from NIKS, NIKSmcHPV18, and HeLa cells. ChIP assay was carried out using 1123 
antibodies specific to unmodified histone H3 (H3), dimethylated lysine 4 of H3 (H3K4me2), 1124 
dimethylated lysine 9 of H3 (H3K9me2), or IgG as control. Immunoprecipitated promoter 1125 
sequences were measured by qPCR, and CT values for the samples were equated to input CT 1126 
values to give percent of input values for comparison. Values are representative of three 1127 
independent experiments. Error bars indicate SD *P< 0.05, **P< 0.01; unpaired t-test compared 1128 
with NIKS cells.  1129 
 1130 
FIGURE 8. HPV18 impairs IRFs binding activity to the IRF element sequence. (A) Linear 1131 
depiction of IFN-β and IFN-λ1 enhancer probes containing the IFN-regulatory factor element 1132 
(IRFE). (B) ELISA-based analysis to assess IRF1, IRF3, and IRF7 binding activity in nuclear 1133 
extracts (5 μg) from NIKS, NIKSmcHPV18, and HeLa cells mock-transfected or transfected 1134 
with 1.25 μg poly(dA:dT) for the time points indicated. The probes described in panel A was 1135 
used as capture probe, and anti-IRF1, anti-IRF7, and anti-IRF3 as detection antibodies. OD 1136 
indicates optical density. The data are presented as mean values of biological triplicates for the 1137 
IFN-β enhancer. Error bars indicate SD *P< 0.05, **P< 0.01; one-way ANOVA followed by 1138 
Bonferroni’s post test compared with cells mock-transfected.  1139 
 1140 
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FIGURE 9. Schematic model of the innate immune response to poly(dA:dT) stimulation in 1141 
NIKSmcHPV18 vs. NIKS cells. (TBK-1: TANK-binding kinase 1) 1142 








